Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Basal Cell 14Neoplasms 4Pancreatic Neoplasms 3Skin Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Medulloblastoma 2Colorectal Neoplasms 2Chondrosarcoma 2Basal Cell Nevus Syndrome 2Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Solid Cancers 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Pancreatic Diseases 1Osteosarcoma 1Odontogenic Cysts 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Unknown Primary 1Neoplasms, Basal Cell 1Neoplasms by Site 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1

Interventions

Risk Factors 1HhAntag691 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms, Basal Cell × HhAntag691 × Clear all
NCT00833417 2026-05-11

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma

Genentech, Inc.

Phase 2 Completed
104 enrolled 13 charts
Dermatologic

Carcinoma, Basal Cell, Neoplasms, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡